{"id":"stable-erythropoietin-therapy","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of thromboembolic events"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Erythropoietin is a hormone that promotes the formation of red blood cells in the bone marrow. By providing a stable form of erythropoietin, this therapy helps to increase red blood cell production, which can help to alleviate anemia in patients with chronic kidney disease or other conditions.","oneSentence":"Stable erythropoietin therapy works by stimulating the production of red blood cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:02.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with chemotherapy"}]},"trialDetails":[{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT07319468","phase":"NA","title":"Effect of Exercises on Hemodialysis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-01-01","conditions":"Hemodialytic Patients","enrollment":69},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT04410198","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-05-26","conditions":"Anemia Associated With End Stage Renal Disease (ESRD)","enrollment":203},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT01244763","phase":"PHASE2","title":"Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-10-29","conditions":"Chronic Kidney Disease, Anemia","enrollment":145},{"nctId":"NCT01147666","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-05-17","conditions":"End Stage Renal Disease, Anemia","enrollment":161},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741},{"nctId":"NCT03029247","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-27","conditions":"Anaemia","enrollment":105},{"nctId":"NCT00236938","phase":"PHASE3","title":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2002-07","conditions":"Anemia","enrollment":121},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT00236951","phase":"PHASE3","title":"Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2003-02","conditions":"Anemia","enrollment":224},{"nctId":"NCT00551603","phase":"PHASE4","title":"Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules","status":"WITHDRAWN","sponsor":"Anemia Working Group Romania","startDate":"2006-07","conditions":"Bio-Equivalency of 2 Treatment Schedules in HD Patients","enrollment":""},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT02238080","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Chronic Kidney Diseases","enrollment":197},{"nctId":"NCT00605293","phase":"PHASE3","title":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":101},{"nctId":"NCT01888003","phase":"NA","title":"The Benefits of a Preoperative Anemia Management Program","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2013-04","conditions":"Anemia, Iron-Deficiency","enrollment":51},{"nctId":"NCT00356733","phase":"PHASE3","title":"Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2007-01","conditions":"Heart Failure, Congestive, Renal Insufficiency, Chronic","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"stable erythropoietin therapy","genericName":"stable erythropoietin therapy","companyName":"American Regent, Inc.","companyId":"american-regent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stable erythropoietin therapy works by stimulating the production of red blood cells. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}